test

Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer

Conditions

Non-Small Cell Lung Cancer (NSCLC)

What is the purpose of this trial?

This is a dose escalation study that will assess the safety of Vorinostat, a Histone Deacetylase (HDAC) inhibitor, in combination with palliative radiotherapy in patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC). Vorinostat has been approved for use in patients with cutaneous T-cell lymphomas, but several pre-clinical studies suggest activity in lung cancer cell lines. Several HDAC inhibitors,including Vorinostat, may enhance the effect of radiotherapy, and this study will seek to confirm this.



Participation Guidelines

Age:
18 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Merck Sharp & Dohme Corp.
Yale University
Dates:
May 2009
Last Updated:
December 7, 2012
Study HIC#:
0811004507

Clinicaltrials.gov ID: NCT00821951